Pentoxifylline for diabetic kidney disease

作者：Dan Shan, Hong Mei Wu, Qi Yuan, Jun Li, Rong Le Zhou, Guan J Liu · 发表于：Cochrane Database of Systematic Reviews · 年份：2012 · DOI：10.1002/14651858.cd006800.pub2 · 被引用次数：62 · 研究领域：Chronic Kidney Disease and Diabetes、Dialysis and Renal Disease Management、Diabetes Treatment and Management

BACKGROUND: Diabetic kidney disease (DKD) is associated with increased morbidity and mortality, mostly relating to cardiovascular complications. The relevance of inflammation in the pathogenesis of DKD has been investigated in recent years, and it has been shown that inflammatory markers are higher in people with DKD compared with the wider population. Pentoxifylline is a methylxanthine phosphodiesterase inhibitor with favourable anti-inflammatory effects and immunoregulatory properties. The anti-inflammatory effects conferred by pentoxifylline may be beneficial in the management of DKD. OBJECTIVES: To assess the benefits and harms of pentoxifylline for treating people with DKD. SEARCH METHODS: We searched the Cochrane Renal Group's specialised register (January 2012), CENTRAL (Issue 12, 2011), MEDLINE, EMBASE and four Chinese biomedical literature databases (CBM-disc, 1979 to July 2009), Chinese Science and Technique Journals Database (VIP, until July 2009), China National Knowledge Infrastructure (CNKI, until July 2009) and WanFang database (until July 2009). SELECTION CRITERIA: All randomised controlled trials (RCTs) and quasi-RCTs studying the benefits and harms of pentoxifylline for DKD. DATA COLLECTION AND ANALYSIS: Data were extracted independently by two authors. Meta-analyses were performed when more than one study provided data on a comparable outcome in sufficiently similar patients. Results of dichotomous outcomes were expressed as risk ratios (RR) with 95% confid...